

## Press Release

### NextPharma invests €15 million to increase oral solid dosage form manufacturing and packaging capacity at its Goettingen site

Goettingen, Germany, 9 October 2020

As part of NextPharma's ongoing strategy to continue to invest significantly in our existing sites, in order to both increase capacity and to improve efficiency with modern state-of-the-art equipment, we have recently completed a €15 million investment at our Goettingen site. The investment project, which was completed within 12 months, will expand our existing capacity in manufacturing and packaging of oral solid dosage forms in line with the highest quality and equipment standards.



The project involved construction of a new 1,000 m<sup>2</sup> building on two levels, with additional production facilities on the ground floor for mixing, compression, film coating and granulation. The investment has increased capacity at the site by 25%, equivalent to an increase in manufacturing and packaging capacity of approximately one billion tablets.



A high-performance packaging line for blister packs has been installed on the upper floor of the building, and another bottle packaging line will be added in Q2 2021. The entire building is controlled with the most up-to-date building control and ventilation (HVAC) technology. The building and its facilities became operational in Q3 2020.

Peter Burema, CEO, commented: "We are very happy to support both our existing and new customers' product supply with this

state-of-the-art additional capacity, which also represents a significant step in NextPharma's growth strategy as a leading Europe-based CDMO. Although today we celebrate the additional competitive capacity of solid dosage forms at our Goettingen site, we also continue to invest across all of our sites and capabilities, as we consider this to be imperative in order to meet the challenge of product supply within the pharmaceutical market, which has become even more visible during the Covid-19 crisis."

Please feel free to contact us to discuss this exciting evolution of our Goettingen site!

- ENDS -

#### For more information contact:

Dr. Georg Althaus, Site Manager, NextPharma Goettingen, +49 551 382-0,  
[georg.althaus@nextpharma.com](mailto:georg.althaus@nextpharma.com)

Peter Burema, Chief Executive Officer, NextPharma, +44 203 585 4120,  
[peter.burema@nextpharma.com](mailto:peter.burema@nextpharma.com)

## **Press Release**

### **Notes to editors**

#### **About NextPharma**

NextPharma is a leading European pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with a current footprint spanning five sites in Germany, one in France and one in Finland. NextPharma supplies products globally, with six of its seven sites FDA-approved. With expertise in solids, semi solids and non-sterile and sterile liquids, the company provides services from pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms including tablets, capsules, granules, powders, pellets, gels, creams, sprays and syrups. Additionally, it provides a wide range of packaging solutions including blow-fill-seal, blisters, bottles, sachets, stick packs and tubes. NextPharma's expertise and centres of excellence enable it to provide a unique service offering in certain very specific specialised areas such as hormonal solids and semi-solids, cephalosporins, penicillins, narcotics, modified release products, ophthalmics as well as paediatric medicinal products.

For more information, please visit [www.nextpharma.com](http://www.nextpharma.com)